register

Medical and Science

Primary care series to address perceived age bias in bowel cancer

Health Industry Hub | June 28, 2024 |

Medical: Studies reveal that younger individuals with bowel cancer often endure a prolonged period of 3 months to 5 years consulting multiple doctors before receiving a diagnosis, sometimes requiring 10 or more visits to GPs.

Bowel Cancer Australia today launched the Never2Young CPD series, a range of GP educational activities to help overcome perceived age bias by people under age 50 diagnosed with bowel cancer.

The series was developed in response to requests from early-onset bowel cancer advocates and recent Australian research which cited the mounting imperative for GPs to receive more information and clinical guidance on early-onset bowel cancer specific diagnosis.

Patients perceived their GPs’ low suspicion of cancer given their age as an age bias that shaped the nature of clinical assessments, influenced the investigations conducted and referrals given, and created tensions between patients and doctors which obstructed shared decision-making.

Bowel Cancer Australia CEO Julien Wiggins said “Limited clinical awareness of early-onset bowel cancer presents a challenge for young people seeking diagnosis.”

“Younger patients are often overlooked for bowel cancer which was the motivation for developing this important educational resource,” he added.

“My advice to other young people is to please not ignore symptoms, no matter how embarrassing, and even more important, please don’t allow your doctor/s to be complacent about your symptoms,” advised one participant in a recent patient perspective study.

Another participant emphasised, “It is crucial if you have any symptoms at all that you are concerned with, request to have a further investigation and DO NOT let anyone tell you, you are too young to get bowel cancer!”

The Never2Young CPD series is an approved activity of The Royal Australian College of General Practitioners (RACGP) and The Australian College of Rural and Remove Medicine (ACRRM). The educational activities total 2.5 CPD hours.

From late July, Measuring Outcome (MO) hours can also be earned with two audit activities focused on early-onset bowel cancer in general practice.

Early-onset bowel cancer patients differ from late-onset bowel cancer patients in their diagnostic trajectories; time to diagnosis can be 60% longer with a greater number of missed diagnostic opportunities, and younger people are more likely to be diagnosed in later stages of the disease.

Late-stage diagnosis increases the likelihood of aggressive treatment with physical, psychosocial, and quality of life outcomes that are uniquely challenging for this under-50 patient population, especially with regards to fertility and ostomy management.

International analysis of nearly 25 million patients younger than 50 published in JAMA Network Open, found nearly half of individuals (45%) presented with blood in the stool, 40% presented with abdominal pain, and more than one-quarter (27%) presented with altered bowel habits.

Blood in the stool and abdominal pain were associated with a 5 to 54-fold and 1.3 to 6-fold increased likelihood of early-onset bowel cancer, respectively.

1,716 Australians are diagnosed with bowel cancer under age 50 each year and it is the deadliest cancer for Australians aged 25-44.

In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government's rejection of COVID Royal Commission a stark contrast to the UK and NZ

Government’s rejection of COVID Royal Commission a stark contrast to the UK and NZ

Health Industry Hub | September 20, 2024 |

The Albanese government has dismissed the Senate legal and constitutional committee’s proposal for a COVID-19 pandemic royal commission with one […]

More


News & Trends - Biotechnology

AusBiotech and MTPConnect Unite for Landmark Summit on Australia’s Biotech and Medtech Future

AusBiotech and MTPConnect unite for landmark Summit on the nation’s biotech and medtech future

Health Industry Hub | September 20, 2024 |

AusBiotech and MTPConnect have announced an ambitious new collaboration to host Australia’s first National Biotech and Medtech Development and Commercialisation […]

More


ESG

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Wear It Red Day ignites national movement for chronic pain recognition, demanding voices be heard

Health Industry Hub | September 20, 2024 |

Today marks the first ever national Wear It Red Day. An initiative of Painaustralia, the national peak advocacy body for […]

More


News & Trends - Pharmaceuticals

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients

Targeted therapy with Astellas’ Xtandi improves prostate cancer outcomes for Aussie patients: New study

Health Industry Hub | September 20, 2024 |

Pharma News: New research from the led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) […]

More


This content is copyright protected. Please subscribe to gain access.